AGS Therapeutics Announces Move to Spartners, the already Prestigious Accelerator within the Paris-Saclay Life Sciences Hub
PARIS, FRANCE (May 30, 2023) – AGS, a preclinical-stage biotech company pioneering microalgae extracellular vesicles (MEV) as a novel universal delivery system for innovative therapeutics, today announced its moving into Spartners, a unique world-class accelerator resulting from a ground-breaking collaborative platform between Servier and BioLabs to support the development of promising biotech companies.
AGS is the first company to move into Spartners, following a rigorous selection process involving a committee of representatives from BioLabs, a highly-renowned international incubator network in the US, Europe, and Japan; and Servier, a leading global pharmaceutical company, operating the Research and Development Institute that hosts Spartners; as well as BPIFrance, a public investment bank; France Biotech, the French biotech trade organisation; the SATT Network, a group of thirteen technology transfer acceleration companies; and Medicen, a network of health innovation organisations. To know more
